AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12669236 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and high-dose intravenous etoposide (group 2; n=84)
Number of subjects: 285
Study 10723836 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of recommended coping strategies (setting goals for drinking, keeping track of drinking, pacing drinking, planning ahead to avoid heavy drinking, developing free-time activities, coping with problems without drinking)
Number of subjects: 155
Study 10723836 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of recommended coping strategies (setting goals for drinking, keeping track of drinking, coping with problems without drinking)
Number of subjects: 155
Study 8626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 15
Study 8626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (30 mg)
Number of subjects: 15
Study 8626987 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (250 mg)
Number of subjects: 15
Study 1428784 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine‐sulfadiazine
Number of subjects: 39
Study 1428784 — intervention group
Group type: COMPARATOR
Intervention: pyrimethamine‐clindamycin
Number of subjects: 39
Study 6703005 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.25 D with 2 delta base-in each eye (plus with prism group)
Number of subjects: 0
Study 6703005 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50 D near addition (bifocal group)
Number of subjects: 0
Study 6703005 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no. 1 pink tint)
Number of subjects: 0
Study 30605397 — intervention group
Group type: COMPARATOR
Intervention: VIG (70% V̇o2peak‐reserve)
Number of subjects: 130
Study 30605397 — intervention group
Group type: COMPARATOR
Intervention: BIKE
Number of subjects: 130
Study 30605397 — intervention group
Group type: COMPARATOR
Intervention: MOD (50% V̇o2peak‐reserve)
Number of subjects: 130
Study 29116949 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused interventions targeting diet and physical activity (PA) behaviors post-cardiac rehabilitation.
Number of subjects: 11
Study 27093063 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 46
Study 27093063 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 46
Study 24424109 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic preparation of 4.2 mg fentanyl
Number of subjects: 20
Study 24424109 — intervention group
Group type: COMPARATOR
Intervention: Durogesic patch of 4.2 mg fentanyl
Number of subjects: 20
Study 22964716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UDCA (1 g/day during 3 weeks before surgery) and RIFA (600 mg/day during 1 week before surgery)
Number of subjects: 20
Study 22964716 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 20026112 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 0
Study 20026112 — intervention group
Group type: COMPARATOR
Intervention: G-CSF deficiency
Number of subjects: 0
Study 18773747 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 18773747 — intervention group
Group type: EXPERIMENTAL
Intervention: New effective and efficient preventive strategies
Number of subjects: 0
Study 16078340 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 30
Study 16078340 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 30
Study 16078340 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) after self-monitoring
Number of subjects: 30
Study 12425756 — intervention group
Group type: EXPERIMENTAL
Intervention: ddAT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2) with prophylactic granulocyte colony-stimulating factor support (5 micro g/kg days 5-10)
Number of subjects: 913
Study 12425756 — intervention group
Group type: COMPARATOR
Intervention: AC-DOC (doxorubicin/cyclophosphamide followed by docetaxel)
Number of subjects: 913
Study 12425756 — intervention group
Group type: EXPERIMENTAL
Intervention: ddAT
Number of subjects: 913
Study 12425756 — intervention group
Group type: COMPARATOR
Intervention: AC-DOC
Number of subjects: 913
Study 12425756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 913
Study 10075362 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompetent calf perforators ligated
Number of subjects: 35
Study 10075362 — intervention group
Group type: COMPARATOR
Intervention: Incompetent calf perforators left intact
Number of subjects: 35
Study 7545361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate Mesilate (FOY) 3g/day infused for 7 days
Number of subjects: 182
Study 7545361 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin (A) 1,500,000 U.I.K./day infused for 7 days
Number of subjects: 182
Study 1645640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 1645640 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 0
Study 7013962 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy before mastectomy
Number of subjects: 930
Study 7013962 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after mastectomy
Number of subjects: 930
Study 7013962 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (Control)
Number of subjects: 930
Study 7013962 — intervention group
Group type: EXPERIMENTAL
Intervention: Gripping force (all groups)
Number of subjects: 930
Study 30608308 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CI therapy)
Number of subjects: 0
Study 30608308 — intervention group
Group type: EXPERIMENTAL
Intervention: CI therapy
Number of subjects: 0
Study 28962558 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER intervention (personalized prevention visit with prevention practitioner)
Number of subjects: 0
Study 28962558 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 0
Study 28962558 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (six month wait list)
Number of subjects: 0
Study 23795976 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 840
Study 23795976 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-LNS
Number of subjects: 840
Study 23795976 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-LNS
Number of subjects: 840
Study 23795976 — intervention group
Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 840
Study 24739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin
Number of subjects: 48
Study 24739994 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 48
Study 23378458 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellmune (250 mg daily for 12 weeks)
Number of subjects: 77
Study 23378458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (self-administered)
Number of subjects: 77
Study 19765608 — intervention group
Group type: EXPERIMENTAL
Intervention: Boy Scout Five‐A‐Day Badge program (9-week program with 30 min weekly troop time and 25 min weekly Internet programming)
Number of subjects: 473
Study 19765608 — intervention group
Group type: EXPERIMENTAL
Intervention: Boy Scout Five‐A‐Day Badge program
Number of subjects: 473
Study 17530530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton controlled release (CR) 1,200 mg BID
Number of subjects: 926
Study 17530530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 926
Study 14998852 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + GEM (Mitomycin C 8 mg/m2 on day 1 + Gemcitabine 2000 mg/m2 on days 1 and 15 every 4 weeks)
Number of subjects: 51
Study 14998852 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + CAPE (Mitomycin C 8 mg/m2 on day 1 + Capecitabine 2000 mg/m2/day on days 1-14 every 4 weeks)
Number of subjects: 51
Study 11514369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma globulin therapy
Number of subjects: 65
Study 11514369 — intervention group
Group type: COMPARATOR
Intervention: Febrile disease controls
Number of subjects: 65
Study 9700472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 2.5 mg/day (L)
Number of subjects: 113
Study 9700472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day (H)
Number of subjects: 113
Study 9700472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 113
Study 8077368 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-endorphin (0.5 mg/h)
Number of subjects: 16
Study 8077368 — intervention group
Group type: COMPARATOR
Intervention: naloxone (5 mg in 5 min)
Number of subjects: 16
Study 8077368 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-endorphin and naloxone
Number of subjects: 16
Study 2807803 — intervention group
Group type: EXPERIMENTAL
Intervention: GE 300/15/80 degrees
Number of subjects: 27
Study 2807803 — intervention group
Group type: EXPERIMENTAL
Intervention: GE 300/15/64 degrees
Number of subjects: 27
Study 2807803 — intervention group
Group type: EXPERIMENTAL
Intervention: SE 250/20
Number of subjects: 27
Study 2807803 — intervention group
Group type: EXPERIMENTAL
Intervention: SE 500/30
Number of subjects: 27
Study 2807803 — intervention group
Group type: EXPERIMENTAL
Intervention: SE 900/30
Number of subjects: 27
Study 8184 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 8184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 8184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30773731 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times a day orally for 2 weeks
Number of subjects: 40
Study 30773731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30773731 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 40
Study 28833521 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group intervention (8 weekly sessions of 1.5 hours each)
Number of subjects: 80
Study 28833521 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group intervention
Number of subjects: 80
Study 28833521 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 25845941 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration (filter group)
Number of subjects: 305
Study 25845941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 305
Study 23219787 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Report group (N = 83)
Number of subjects: 156
Study 23219787 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 73)
Number of subjects: 156
Study 20309015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 182
Study 20309015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 19175852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 198
Study 19175852 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 198
Study 16772442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual fortified salt (DFS) with 3 mg Fe/g salt as ground FePP
Number of subjects: 123
Study 16772442 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt (IS)
Number of subjects: 123
Study 16772442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 15390350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alpha
Number of subjects: 14
Study 15390350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11520368 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen (paclitaxel 60 mg/m2, carboplatin AUC 2)
Number of subjects: 29
Study 11520368 — intervention group
Group type: COMPARATOR
Intervention: Monthly regimen (paclitaxel 175 mg/m2, carboplatin AUC 6)
Number of subjects: 29
Study 11520368 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen
Number of subjects: 29
Study 11520368 — intervention group
Group type: COMPARATOR
Intervention: Monthly regimen
Number of subjects: 29
Study 9777130 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase administration
Number of subjects: 15000
Study 9777130 — intervention group
Group type: COMPARATOR
Intervention: Front-loaded alteplase regimen
Number of subjects: 15000
Study 9777130 — intervention group
Group type: COMPARATOR
Intervention: Double bolus alteplase administration
Number of subjects: 15000
Study 9777130 — intervention group
Group type: COMPARATOR
Intervention: COBALT trial (control group)
Number of subjects: 15000
Study 7890014 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg bd)
Number of subjects: 24
Study 7890014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU daily)
Number of subjects: 24
Study 7890014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3418579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube present
Number of subjects: 0
Study 3418579 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative sputum culture
Number of subjects: 0
Study 3418579 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiographic changes
Number of subjects: 0
Study 3418579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasogastric tube)
Number of subjects: 0
Study 29320591 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer with 7% sweet almond oil and 2% colloidal oatmeal
Number of subjects: 0
Study 27230863 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Internet intervention (Deprexis) adjunctive to usual care
Number of subjects: 1013
Study 27230863 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 1013
Study 25017534 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time outreach intervention including letter notification and electronic message to physician
Number of subjects: 1999
Study 25017534 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time outreach intervention
Number of subjects: 1999
Study 25017534 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard asthma care management)
Number of subjects: 1999
Study 23189301 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged dental implants in organ transplant patients
Number of subjects: 20
Study 23189301 — intervention group
Group type: COMPARATOR
Intervention: Submerged dental implants in control patients
Number of subjects: 20
Study 22009948 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Minimally Invasive Approach (MMIA)
Number of subjects: 91
Study 22009948 — intervention group
Group type: COMPARATOR
Intervention: Traditional Operative Approach (TOPA)
Number of subjects: 91
Study 18176645 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal varnish (CV)
Number of subjects: 116
Study 18176645 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat
Number of subjects: 116
Study 18176645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Comfort Bond Plus Desensitizer
Number of subjects: 116
Study 18176645 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fluoride iontophoresis
Number of subjects: 116
Study 15729523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 34
Study 15729523 — intervention group
Group type: COMPARATOR
Intervention: Unilateral pallidotomy
Number of subjects: 34
Study 12883589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 0
Study 12883589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg
Number of subjects: 0
Study 12883589 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine without Ranitidine
Number of subjects: 0
Study 10931390 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment combined with HAART
Number of subjects: 0
Study 10931390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9298163 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% xylitol in enzyme-containing dentifrice
Number of subjects: 50
Study 9298163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% xylitol in enzyme-containing dentifrice
Number of subjects: 50
Study 8314646 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk exercise response
Number of subjects: 855
Study 8314646 — intervention group
Group type: COMPARATOR
Intervention: Low risk exercise response
Number of subjects: 855
Study 8314646 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of ST-depression, occurrence of angina, and low peak load at exercise
Number of subjects: 855
Study 2942599 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of HB‐VAX vaccine
Number of subjects: 605
Study 2942599 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms of HB‐VAX vaccine
Number of subjects: 605
Study 31705154 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under current local resources
Number of subjects: 607
Study 31705154 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under assumed ideal conditions
Number of subjects: 607
Study 29555019 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment with precise treatment expectations
Number of subjects: 62
Study 29555019 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 62
Study 29555019 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural correlates observed in the periaqueductal gray and rostral ventromedial medulla
Number of subjects: 62
Study 27211225 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based counseling intervention
Number of subjects: 60
Study 27211225 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized counseling
Number of subjects: 60
Study 26537136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernioplasty with mesh (Lichtenstein technique)
Number of subjects: 263
Study 26537136 — intervention group
Group type: COMPARATOR
Intervention: Hernioplasty without mesh (Bassini technique)
Number of subjects: 263
Study 23771450 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence counseling and twice weekly short message reminders for four months
Number of subjects: 104
Study 23771450 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 104
Study 19830412 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous visual feedback (CF) during task execution
Number of subjects: 0
Study 19830412 — intervention group
Group type: COMPARATOR
Intervention: Post-trial visual feedback (PF)
Number of subjects: 0
Study 18815991 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Number of subjects: 0
Study 18815991 — intervention group
Group type: COMPARATOR
Intervention: Writing control
Number of subjects: 0
Study 16650482 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Schema Questionnaire-Short Form (YSQ-SF)
Number of subjects: 1104
Study 12862331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-heat acclimation (HA); 90 min x d(‐1), 40 degrees C for 7 days
Number of subjects: 17
Study 12862331 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 17
Study 11034942 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (6 micromol/L over 20 minutes)
Number of subjects: 80
Study 11034942 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 11034942 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123
Number of subjects: 80
Study 8607953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Number of subjects: 20
Study 8607953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30610380 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cortical potential neurofeedback (SCP-NF)
Number of subjects: 0
Study 30610380 — intervention group
Group type: COMPARATOR
Intervention: Electromyogram biofeedback (EMG-BF)
Number of subjects: 0
Study 30587219 — intervention group
Group type: EXPERIMENTAL
Intervention: vixotrigine
Number of subjects: 125
Study 30587219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 27333019 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutment
Number of subjects: 24
Study 27333019 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutment
Number of subjects: 24
Study 24268369 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR: 25% reduction in energy intake, n=12)
Number of subjects: 35
Study 24268369 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + exercise (CR+EX: 12.5% reduction in energy intake + 12.5% increase in exercise energy expenditure, n=12)
Number of subjects: 35
Study 24268369 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy weight-maintenance diet, n=11)
Number of subjects: 35
Study 22850688 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxcarbazepine (OXC‐MR)
Number of subjects: 71
Study 22850688 — intervention group
Group type: COMPARATOR
Intervention: Immediate release oxcarbazepine (OXC‐IR)
Number of subjects: 71
Study 18349194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1%
Number of subjects: 50
Study 18349194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1.5%
Number of subjects: 50
Study 18349194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion scheme to increase target concentration by 0.3%
Number of subjects: 50
Study 18349194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion scheme to decrease target concentration by 0.3%
Number of subjects: 50
Study 17152332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner
Number of subjects: 200
Study 17152332 — intervention group
Group type: COMPARATOR
Intervention: Resident
Number of subjects: 200
Study 14640465 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20-80 mg)
Number of subjects: 0
Study 14640465 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 0
Study 14640465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0